n (%) | Natalizumab-treated patients (N = 222) |
---|---|
Patients with ≥1 SAE | 13 (5.9) |
Patients with ≥1 treatment-related SAE | 1 (0.5)b |
Patients with ≥1 SAE leading to death | 1 (0.5)c |
SAE by preferred termd | |
Suicide attempt | 2 (0.9) |
Acute kidney injury | 1 (0.5) |
Anaphylactic reactione | 1 (0.5) |
Bronchial obstruction | 1 (0.5) |
Clostridium difficile colitis | 1 (0.5) |
Conversion disorderf | 1 (0.5) |
Hydronephrosis | 1 (0.5) |
Hyperkalemia | 1 (0.5) |
Hypotension | 1 (0.5) |
Ileus | 1 (0.5) |
Melanoma recurrent | 1 (0.5) |
Migraine | 1 (0.5) |
Overdose | 1 (0.5) |
Posttraumatic headache | 1 (0.5) |
Radial nerve palsy | 1 (0.5) |
Respiratory failure | 1 (0.5) |
Unresponsive to stimuli | 1 (0.5) |
Ureterolithiasis | 1 (0.5) |